Roivant Sciences Ltd
Closed
SectorHealthcare
29.58 4.15
Overview
Share price change
24h
Min
28.51
Max
29.75
Income | 669M 356M |
|---|---|
Sales | 521K 2.5M |
Profit margin | 14,116.825 |
Employees | 721 |
EBITDA | -65M -354M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +25.75% upside |
Market Cap | 255M 20B |
|---|---|
Previous open | 25.43 |
Previous close | 29.58 |
Roivant Sciences Ltd Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Roivant Sciences Ltd Forecast
Price Target
By TipRanks
25.75% upside
12 Months Forecast
Average 36.53 USD 25.75%
High 42 USD
Low 29.29 USD
Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Roivant Sciences Ltd
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
